BrosMed Medical Announces Japanese Approval and Launch of Artimes™ and Apollo™ PTCA In Japan Market
BrosMed Medical Announces Japanese Approval and Launch of Artimes™ and Apollo™ PTCA In Japan Market
Aug 30th , 2017—BrosMed Medical announces Japan PMDA approval of its Artimes™ and Apollo™ PTCA balloons, and formally launches in Japan. Artimes™ and Apollo™ are two PTCA of Brosmed balloon families. Artimes™ is a semi-compliant pre-dilatation PTCA balloon, and Apollo™ is a non-complaint high pressure post-dilatation PTCA balloon. These two balloons are designed for the treatment of percutaneous transluminal coronary angioplasty (PTCA) for the purpose of improving myocardial blood flow in the localized stenotic lesion of the coronary arteries.
Following the approval, BrosMed Medical achieves one more step to its global vision beside current geographical footprint in Europe, USA, China, Asia Pacific, Latin America and Middle East.
“The PMDA approval of Artimes™ and Apollo™ PTCA in Japan is quite exciting and significant to the company.” said by Stephen Lee, General Manager of BrosMed Medical. “PMDA approval helps BrosMed to penetrate the Japan market and compete ourselves with giant companies and local players in term of products performance and services. We are confident that Artimes™ and Apollo™ would satisfy Japanese physicians’ needs and provide better clinical outcomes. Moreover, we are going to provide our completed PTA portfolio to the Japan market as second step in order to expand us from cardiovascular to endovascular filed.”
Please contact our regional distributors and/or our sales at sales@brosmed.com for more products details.
About BrosMed Medical
BrosMed Medical is more than just a company; we are leading the medical device design and manufacturing revolution.
BrosMed Medical develops, manufactures and markets medical devices primarily used by interventional cardiologists, radiologists and vascular surgeons in angioplasty procedures and other minimal invasive devices.
We provide solutions to our customers through innovative design, effective supply chain management, world-class manufacturing, and flexible channels of distribution and through the development or acquisition of innovative technologies.
BrosMed Medical product portfolio consist of, Artimes™ PTCA, Apollo™NC PTCA, Atropos™ 0.035 PTA, Minerva™ 0.018 PTA, Polux™ 0.014 PTA, Hermes™ NC 0.035 PTA, Achilles™ NC 0.018 PTA, Castor™ NC 0.014 PTA, Conger™ Hydrophilic coated wireandFreepath™ Catheter Sheath Introducer. BrosMed Medical is supplying safe, effective and hi-tech medical devices in 30 countries.
